• This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Sun - Fri 8:00 - 20:30
Bioethanol as a Biofuel and an Alcoholic Drink

Green Science Alliance Developed an Effective Method for Making Bioethanol from Plants, Wood, Wood Waste, Paper Waste and Food Waste. The Challenge Now is to Use Bioethanol as a Biofuel and an Alcoholic Drink

Global warming is a serious problem, mainly because of the increase in greenhouse gases such as methane and carbon oxide (CO2), as well as society's dependence on petroleum products. Large amounts of money have been spent to research and develop new kinds of energy sources instead of petroleum-based fuel.

Read more →
Vecuronium Bromide for Injection

Sun Pharmaceutical Industries, Inc. Issues Voluntary Nationwide Recall of Vecuronium Bromide for Injection

Sun Pharmaceutical Industries, Inc. (SPII), a wholly owned subsidiary of Sun Pharmaceutical Industries, Ltd. is voluntarily recalling three lots of Vecuronium Bromide for Injection, 10 mg (lyophilized powder), and one lot of Vecuronium Bromide for Injection, 20 mg (lyophilized powder) to the hospital level.

Read more →
Expansion of Lead Asset AD04 into Opioid Addiction

Adial Pharmaceuticals Announces Planned Expansion of Lead Asset AD04 into Opioid Addiction Including Synthetic Opioids Such as Fentanyl

Adial Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced plans to expand activities around the Company’s lead asset, AD04, beyond alcohol use disorder (AUD), to now include its potential use in patients with opioid use disorder.

Read more →
Theranova

Baxter Highlights Clinical Data at ASN: Kidney Week Showing How New Technologies Are Advancing Dialysis Care across Modalities

Baxter International Inc. (NYSE:BAX), a global innovator in renal care, highlighted findings from HDx (expanded hemodialysis) and peritoneal dialysis (PD) studies presented at the American Society of Nephrology (ASN): Kidney Week, Oct. 23-28, showing how novel renal care technologies are positively impacting patient care and clinic efficiency.

Read more →
Adial Pharmaceuticals

Addiction Drug Developer Adial Pharmaceuticals Successfully Passes Patent Opposition Period in Europe for AD04 in Alcohol Use Disorder; Reports no Challenges to European Patent

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced the strengthening of its intellectual property (IP) portfolio, as it has successfully passed the patent opposition period in Europe..

Read more →

We use cookies to ensure you get the best experience on this website Privacy Policy